The aim of the Early Access to Medicines scheme is to make promising new medicines obtainable to patients sooner. This programme was set up in 2014 and is run by the Medicines and Healthcare Projects Regulatory Agency (MHRA), which are a UK government organisation. The role of the MHRA is to ensure that all medicines and equipment used in healthcare work and are safe.

Medications for myasthenia gravis currently available through EAMS are:

• Efgartigimod alfa 

To visit the EAMS page on the UK government website, click here 

Treatments